Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on June 17, 2021, regarding an event that occurred on June 7, 2021. The Company is a biotechnology firm focused on enzyme engineering.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for a reporting period. The only specific financial figure disclosed is the value of a new commercial agreement.
- Transaction Value: Approximately $13.9 million (extended price of the Purchase Order).
Material Changes and Events
On June 7, 2021, Codexis accepted a binding purchase order from an undisclosed global pharmaceutical company for a proprietary enzyme product. This enzyme is intended for use in the manufacture of the customer's undisclosed active pharmaceutical ingredient (API).
Guidance, Outlook, and Risks
Delivery of the enzyme and the realization of revenue are subject to several conditions, including:
- Timing of required regulatory approvals for the customer's API.
- Completion of Codexis's registration of the enzyme under the European Union's REACH legislation.
Management notes that statements regarding potential receipt of payments are forward-looking and involve substantial risks and uncertainties. The filing directs investors to the Company's Form 10-K (filed March 1, 2021) and Form 10-Q (filed May 7, 2021) for a detailed description of business risks.
Key Facts for Investor Verification
- Verify the status of the customer's regulatory approvals for the API utilizing the enzyme.
- Confirm the timeline for Codexis's REACH registration completion in the European Union.
- Review the Company's recent 10-K and 10-Q filings for historical financial performance and liquidity position, as this 8-K contains no such data.
- Monitor future filings for updates on the delivery schedule and revenue recognition related to the $13.9 million order.